Key Takeaways
- Gilead Sciences has entered an agreement to purchase German biotechnology firm Tubulis GmbH in a transaction valued at up to $5 billion, including $3.15 billion in immediate cash payments.
- This acquisition strengthens Gilead’s portfolio of antibody-drug conjugates (ADCs), focusing on treatment areas such as ovarian malignancies and non-small cell lung cancer.
- RBC Capital has increased its GILD price objective from $118 to $123, while maintaining its Sector Perform rating on the stock.
- According to RBC analysis, Yeztugo may surpass first-quarter expectations by approximately $180 million, though concerns remain about adherence rates and market growth pace.
- Multiple investment firms including Cantor Fitzgerald, UBS, and Deutsche Bank maintain positive ratings with price objectives reaching as high as $155.
Gilead Sciences (GILD) is strengthening its oncology division through an acquisition agreement with Munich-headquartered Tubulis GmbH, valued at up to $5 billion in all-cash consideration.
The transaction structure includes an initial payment of $3.15 billion, with an additional $1.85 billion contingent upon achieving specific development and commercial milestones. Gilead intends to finance this acquisition through existing cash reserves and newly issued senior unsecured debt instruments, targeting completion during the second quarter of 2026.
Tubulis specializes in developing antibody-drug conjugates, an innovative cancer treatment approach that delivers chemotherapy agents directly to malignant cells while minimizing damage to surrounding healthy tissue. The company’s most advanced candidate, TUB-040, is currently undergoing Phase 1b/2 clinical evaluation for platinum-resistant ovarian cancer and non-small cell lung cancer patients.
Chief Executive Officer Daniel O’Day characterized this pipeline enhancement as potentially representing the most robust and diversified collection of assets in the organization’s history.
Shares declined approximately 1.37% following Tuesday’s announcement, a relatively standard market response when companies commit substantial upfront capital to acquisitions.
RBC Increases Price Objective While Maintaining Neutral Position
RBC Capital Markets adjusted its GILD price target upward to $123 from a previous $118, while retaining a Sector Perform rating—effectively a neutral recommendation. The investment firm highlighted encouraging early performance data for Yeztugo, Gilead’s recently launched therapeutic, based on independent prescription tracking metrics.
RBC’s modeling suggests Yeztugo could exceed first-quarter consensus estimates by approximately $180 million, versus the Street’s expectation of $141 million. This represents a substantial variance if the projections materialize.
However, RBC introduced some cautionary notes in its analysis. The firm observed that institutional investor expectations for fiscal year 2026 may already anticipate roughly $1 billion in revenues. Should patient adherence metrics or market penetration rates fall short, these optimistic peak revenue projections could face downward revisions.
Current adherence tracking stands at approximately 70% according to RBC’s industry channel checks—a respectable figure, though one that provides limited cushion for deterioration.
RBC also identified potential softness in other segments. HIV franchise revenues are projected at $4.8 billion compared to the $4.9 billion Street consensus, while Veklury revenues are estimated at $141 million versus analyst expectations of $216 million.
Gilead is scheduled to release first-quarter financial results on April 23.
Wall Street Analysts Maintain Constructive Outlook
Several other research firms express greater optimism. Cantor Fitzgerald reaffirmed its Overweight recommendation with a $155 price objective, highlighting robust prescription momentum throughout Gilead’s HIV product portfolio.
UBS similarly retained its Buy rating, noting a 56% sequential increase in Yeztugo sales during February. Deutsche Bank maintained its Buy rating and $155 target price, forecasting first-quarter Yeztugo revenues of approximately $118 million.
In a separate corporate development, Gilead has extended the acceptance period for its tender offer targeting Arcellx common shares until April 24, 2026. The offer provides $115.00 per share in cash consideration, supplemented by contingent value rights linked to future product revenue achievements.
With first-quarter earnings scheduled for April 23, investors will closely monitor whether Yeztugo’s promising early performance translates into meaningful financial outperformance.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
